Gongxi Qiao

Gongxi Qiao

Auto-generated profile, based on publicly available information

Gongxi Qiao

Laboratory of Quantitative Synthetic Biology Shenzhen Institute of Synthetic Biology Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen Guangdong China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Chemical Engineering Journal
Verified
Journal Article
Closed access
GQGongxi Qiao
Gongxi Qiao
LLLei Liu
Lei Liu
XHXiaoxing Hao
Xiaoxing Hao
JZJunke Zheng
Junke Zheng
WLWanqiang Liu
Wanqiang Liu
QWQianming Wang
Qianming Wang

1 April 2019 in Dyes and Pigments
Verified
Journal Article
Closed access
GQGongxi Qiao
Gongxi Qiao
DLDong Lu
Dong Lu
YTYiping Tang
Yiping Tang
Jinwei GaoJinwei Gao
Jinwei Gao
QWQianming Wang
Qianming Wang

29 March 2024 in Science Advances
Verified
Journal Article
Open access
GQGongxi Qiao
Gongxi Qiao
SLShenglin Li
Shenglin Li
XPXumin Pan
Xumin Pan
PXPing Xie
Ping Xie
RPRuixi Peng
Ruixi Peng
XCXia Chu
Xia Chu
Directly activating CD8 + T cells within the tumor through antigen-presenting cells (APCs) hold promise for tumor elimination. However, M2-like tumor-associated macrophages (TAMs), the most abundant APCs in tumors, hinder CD8 + T cell activation due to inefficient antigen cross-presentation. Here, we demonstrated a personalized nanotherapeutic platform using surgical tumor–derived galactose ligand–modified cancer cell membrane (CM)–coated cysteine protease inhibitor (E64)–loaded mesoporous silica nanoparticles for postsurgical cancer immunotherapy. The platform targeted M2-like TAMs and released E64 within lysosomes, which reshaped antigen cross-presentation and directly activated CD8 + T cells, thus suppressing B16-OVA melanoma growth. Furthermore, this platform, in combination with anti–PD-L1 antibodies, enhanced the therapeutic efficacy and substantially inhibited 4T1 tumor growth. CMs obtained from surgically resected tumors were used to construct a personalized nanotherapeutic platform, which, in synergy with immune checkpoint blockade (ICB), effectively inhibited postsurgical tumor recurrence in 4T1 tumor. Our work offered a robust, safe strategy for cancer immunotherapy and prevention of postsurgical tumor recurrence.

1 January 2019 in Journal of Alloys and Compounds
Verified
Journal Article
Closed access
GQGongxi Qiao
Gongxi Qiao
ZZZhi Zeng
Zhi Zeng
Jinwei GaoJinwei Gao
Jinwei Gao
YTYiping Tang
Yiping Tang
QWQianming Wang
Qianming Wang

6 October 2023 in Chemical Engineering Journal
Verified
Journal Article
Closed access
GQGongxi Qiao
Gongxi Qiao
XPXuming Pan
Xuming Pan
MHMengyun He
Mengyun He
RPRuixi Peng
Ruixi Peng
XHXiangrong Huang
Xiangrong Huang
XCXia Chu
Xia Chu

1 September 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
GQGongxi Qiao
Gongxi Qiao
SLShenglin Li
Shenglin Li
JLJianbin Liu
Jianbin Liu
XPXumin Pan
Xumin Pan
ZGZhichao Gong
Zhichao Gong
XCXia Chu
Xia Chu